Gene BRCC-1 and diagnostic and therapeutic uses thereof
OwnerPrafulla Gokhale, Anatoly Dritschilo +3inventors
InventorsPrafulla Gokhale, Anatoly Dritschilo, Aquilur Rahman, Imran Ahmad, Usha Kasid
Life of this patent
Estimating the term…
Abstract
A gene that is a modulator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of BRCC-1 such as breast cancer and lung cancer.
Claims37
An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:
- (a) a polynucleotide encoding amino acids from about 1 to about 982 of SEQ ID NO:3;
- (b) a polynucleotide encoding amino acids from about 2 to about 982 of SEQ ID NO:3;
- (c) the polynucleotide complement of the polynucleotide of (a) or (b);
- and
- (d) a polynucleotide at least 90% identical to the polynucleotide of (a), (b) or (c).
An isolated nucleic acid molecule comprising about 3 to about 3722 contiguous nucleotides from SEQ ID NO:2.
An isolated nucleic acid molecule comprising about 50 to about 300 contiguous nucleotides from SEQ ID NO:2.
An isolated nucleic acid molecule comprising about 2 to about 324 contiguous nucleotides of SEQ ID NO:2.
An isolated nucleic acid molecule comprising about 40 to about 250 contiguous nucleotides from SEQ ID NO:2.
An isolated nucleic acid molecule comprising a polynucleotide encoding a polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has an amino acid sequence selected from the group consisting of:
- (a) amino acids from about 1 to about 982 of SEQ ID NO:3;
- and
- (b) amino acids from about 2 to about 982 of SEQ ID NO:3.
An isolated polypeptide comprising amino acids at least 95% identical to amino acids selected from the group consisting of:
- (a) amino acids from about 1 to about 982 of SEQ ID NO:3;
- and
- (b) amino acids from about 2 to about 982 of SEQ ID NO:3.
An isolated polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has an amino acid sequence selected from the group consisting of:
- (a) amino acids from about 1 to about 982 of SEQ ID NO:3;
- and
- (b) amino acids from about 2 to about 982 of SEQ ID NO:3.
An isolated polypeptide comprising amino acids selected from the group consisting of:
- (a) amino acids from about 1 to about 982 of SEQ ID NO:3;
- and
- (b) amino acids from about 2 to 982 of SEQ ID NO:3.
An epitope-bearing portion of the polypeptide identified in FIG. 6.
A method of modulating apoptosis or proliferation of a cancer cell, comprising regulating expression of BRCC-1 in said mammalian cell.
An antisense oligonucleotide that inhibits the expression of BRCC-1 in a mammalian cell.
A method of treating cancer characterized by BRCC-1 overexpression by administration of an antisense oligonucleotide or ribozyme that modulates BRCC-1 expression.
A method of treating cancer characterized by BRCC-1 overexpression comprising administering an antibody that specifically binds BRCC-1.
A method of detecting cancer characterized by BRCC-1 overexpression or BRCC-1 underexpression comprising detecting the levels of BRCC-1 expression and correlating said level of expression to the presence or absence of cancer.
A method for modulating cancer cell proliferation and/or metastasis in a cancer patient comprising administering a ribozyme or antisense oligonucleotide that modulates BRCC-1 expression.
A method of treating a condition characterized by BRCC-1 underexpression comprising administering an agent that promotes BRCC-1 expression.
A method of treating a condition characterized by BRCC-1 underexpression comprising administering an BRCC-1 peptide or a fragment thereof.
A method for inhibiting cancer cell proliferation and/or metastasis in a cancer patient comprising administering a small molecule inhibitor of BRCC-1;
- an antibody that specifically binds BRCC-1;
- a ribozyme or antisense oligonucleotide that modulates BRCC-1 expression in combination with radiotherapy;
- chemotherapy, hormone, biological anticancer agent;
- hormones or inhibitors of cell cycle dependent kinases.
A method for treating cancer comprising administering BRCC-1 cDNA that leads to overexpression of BRCC-1, thereby inhibiting cancer cell proliferation and/or metastatic potential.
A pharmaceutical composition for the treatment of cancer that comprises an agent promoting the overexpression of BRCC-1 or its activity and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.